ClinicalTrials.gg

Program

andecaliximab

Also written as “Andecaliximab”, “GS-5745” and “GS-5745 SC”.

Its studies are mostly in Colitis, Ulcerative · Arthritis, Rheumatoid · Myositis Ossificans · Ossification, Heterotopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.

Furthest: phase 3, since Aug 7, 201514 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences120 open or runningphase 3since Aug 7, 2015Feb 27, 2013none ahead
Ashibio22 open or runningphase 3since Jun 17, 2024Jun 17, 2024Dec 2028phase 2 · NCT07024407

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2013First study: phase 1 study in Pancreatic NeoplasmsNew to Gilead SciencesGilead Sciences · NCT01803282 · 236 enrolled · United States
  2. Apr 8, 2013Phase 1 study in Colitis, UlcerativeGilead Sciences · NCT01831427 · 74 enrolled · United States, Belgium, Canada and more
  3. Feb 28, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveGilead Sciences · NCT02077465 · 11 enrolled · United States
  4. Jun 25, 2014Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT02176876 · 18 enrolled · Czech Republic, Hungary
  5. Aug 4, 2014Phase 1 study in Colitis, UlcerativeGilead Sciences · NCT02209987 · 28 enrolled · New Zealand
  6. Mar 27, 2015Phase 2 study in Crohn DiseaseGilead Sciences · NCT02405442 · 187 enrolled · United States, Australia, Canada and more
  7. Aug 7, 2015Phase 3 study in Colitis, UlcerativeGilead Sciences · NCT02520284 · 165 enrolled · United States, Australia, Belgium and more
  8. Sep 8, 2015Phase 3 study in Stomach NeoplasmsGilead Sciences · NCT02545504 · 432 enrolled · United States, Australia, Belgium and more
  9. Apr 29, 2016Phase 2 study in Cystic FibrosisGilead Sciences · NCT02759562 · 6 enrolled · Australia, France, Germany and more
  10. Aug 8, 20162 phase 2 studiesGilead Sciences · NCT02862574, NCT02864381
  11. Aug 8, 2016Phase 1 study in Gastric AdenocarcinomaGilead Sciences · NCT02862535 · 36 enrolled · Japan
  12. Jun 17, 2024Ashibio's first study: phase 3 study in Myositis OssificansNew to AshibioAshibio · NCT06508021 · 92 enrolled · United States
  13. May 20, 2025Phase 2 study in Ossification, HeterotopicAshibio · NCT07024407 · 10 enrolled · United States

Ahead

  1. Dec 2028Primary completion: phase 2 study in Ossification, HeterotopicAshibio · NCT07024407
  2. Feb 4, 2029Primary completion: phase 3 study in Myositis OssificansAshibio · NCT06508021

TargetBeta

MMP9 →read by rule
“A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), ”NCIt, by rule
“Matrix metalloproteinase 9 inhibitor”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07024407Ossification, Heterotopic · United States2Active, not recruitingAshibioDec 202810
NCT06508021Myositis Ossificans · United States3Active, not recruitingAshibioFeb 4, 202992
NCT02864381Gastric Adenocarcinoma · United States, Australia, Belgium and more2CompletedGilead SciencesNov 8, 2017144
NCT02862574Arthritis, Rheumatoid · United States2TerminatedGilead SciencesJun 26, 201715
NCT02862535Gastric Adenocarcinoma · Japan1TerminatedGilead SciencesOct 25, 201936
NCT02759562Cystic Fibrosis · Australia, France, Germany and more2TerminatedGilead SciencesJul 6, 20176
NCT02545504Stomach Neoplasms · United States, Australia, Belgium and more3CompletedGilead SciencesMay 15, 2019432
NCT02520284Colitis, Ulcerative · United States, Australia, Belgium and more3TerminatedGilead SciencesSep 2016165
NCT02405442Crohn Disease · United States, Australia, Canada and more2TerminatedGilead SciencesNov 30, 2016187
NCT02209987Colitis, Ulcerative · New Zealand1CompletedGilead SciencesOct 201428
NCT02176876Arthritis, Rheumatoid · Czech Republic, Hungary1CompletedGilead SciencesApr 201518
NCT02077465Pulmonary Disease, Chronic Obstructive · United States1CompletedGilead SciencesOct 27, 201411
NCT01831427Colitis, Ulcerative · United States, Belgium, Canada and more1CompletedGilead SciencesJan 5, 201574
NCT01803282Pancreatic Neoplasms · United States1CompletedGilead SciencesApr 23, 2019236

How it is read

Names in the registry

  • “Andecaliximab”, 13 entries
  • “GS-5745”, 1 entry
  • “GS-5745 SC”, 1 entry
  • “GS-5745 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.